Abigail Saucier
Family · Eunice, LANPI 1669992798
Payments from drug & device makers
Across 218 payments — averaging $15.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$898
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$804
- Alkermes, Inc.$748
- Otsuka America Pharmaceutical, Inc.$263
- Vanda Pharmaceuticals Inc.$226
- Johnson & Johnson$149
- plus $267 from 9 others
What the payments were for
- Food & beverage$3,355100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$3,355 in reported general payments places this provider in the 85th percentile of 3,610 family providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 14 | $115,297 |
| Invega SustennaPaliperidone Palmitate | 24 | $79,850 |
| RexultiBrexpiprazole | 46 | $75,491 |
| VraylarCariprazine Hcl | 48 | $69,065 |
| LybalviOlanzapine/Samidorphan Malate | 30 | $47,738 |
| TrintellixVortioxetine Hydrobromide | 18 | $13,570 |
| Oxcarbazepine | 108 | $2,745 |
| Aripiprazole | 50 | $1,724 |
| Duloxetine Hcl | 109 | $1,643 |
| Olanzapine | 126 | $1,488 |
| Ziprasidone Hcl | 24 | $1,444 |
| Quetiapine Fumarate | 228 | $1,372 |
| Buspirone Hcl | 130 | $1,370 |
| Mirtazapine | 109 | $1,321 |
| Paliperidone ErPaliperidone | 12 | $1,273 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $34 | $115,29714 claims |
| Johnson & JohnsonInvega Sustenna | $149 | $79,85024 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $263 | $75,49146 claims |
| AbbVieVraylar | $898 | $69,06548 claims |
| Alkermes, Inc.Lybalvi | $748 | $47,73830 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $12 | $13,57018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,610 family providers in Louisiana.
Other family in Eunice
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.